Cargando…

High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study

Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Frade-Sosa, Beatriz, Ponce, Andrés, Ruiz-Esquide, Virginia, García-Yébenes, Maria Jesús, Morlá, Rosa, Sapena, Nuria, Ramirez, Julio, Azuaga, Ana Belen, Sarmiento, Juan Camilo, Cañete, Juan D., Gomez-Puerta, Jose A., Sanmarti, Raimon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774492/
https://www.ncbi.nlm.nih.gov/pubmed/35054349
http://dx.doi.org/10.3390/diagnostics12010182
_version_ 1784636359926874112
author Frade-Sosa, Beatriz
Ponce, Andrés
Ruiz-Esquide, Virginia
García-Yébenes, Maria Jesús
Morlá, Rosa
Sapena, Nuria
Ramirez, Julio
Azuaga, Ana Belen
Sarmiento, Juan Camilo
Cañete, Juan D.
Gomez-Puerta, Jose A.
Sanmarti, Raimon
author_facet Frade-Sosa, Beatriz
Ponce, Andrés
Ruiz-Esquide, Virginia
García-Yébenes, Maria Jesús
Morlá, Rosa
Sapena, Nuria
Ramirez, Julio
Azuaga, Ana Belen
Sarmiento, Juan Camilo
Cañete, Juan D.
Gomez-Puerta, Jose A.
Sanmarti, Raimon
author_sort Frade-Sosa, Beatriz
collection PubMed
description Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis.
format Online
Article
Text
id pubmed-8774492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87744922022-01-21 High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study Frade-Sosa, Beatriz Ponce, Andrés Ruiz-Esquide, Virginia García-Yébenes, Maria Jesús Morlá, Rosa Sapena, Nuria Ramirez, Julio Azuaga, Ana Belen Sarmiento, Juan Camilo Cañete, Juan D. Gomez-Puerta, Jose A. Sanmarti, Raimon Diagnostics (Basel) Article Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis. MDPI 2022-01-13 /pmc/articles/PMC8774492/ /pubmed/35054349 http://dx.doi.org/10.3390/diagnostics12010182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frade-Sosa, Beatriz
Ponce, Andrés
Ruiz-Esquide, Virginia
García-Yébenes, Maria Jesús
Morlá, Rosa
Sapena, Nuria
Ramirez, Julio
Azuaga, Ana Belen
Sarmiento, Juan Camilo
Cañete, Juan D.
Gomez-Puerta, Jose A.
Sanmarti, Raimon
High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title_full High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title_fullStr High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title_full_unstemmed High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title_short High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
title_sort high sensitivity c reactive protein in patients with rheumatoid arthritis treated with antibodies against il-6 or jak inhibitors: a clinical and ultrasonographic study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774492/
https://www.ncbi.nlm.nih.gov/pubmed/35054349
http://dx.doi.org/10.3390/diagnostics12010182
work_keys_str_mv AT fradesosabeatriz highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT ponceandres highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT ruizesquidevirginia highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT garciayebenesmariajesus highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT morlarosa highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT sapenanuria highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT ramirezjulio highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT azuagaanabelen highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT sarmientojuancamilo highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT canetejuand highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT gomezpuertajosea highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy
AT sanmartiraimon highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy